Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMS) is dated January 25, 2019. The report details the entry into two new material definitive credit agreements and the termination of an existing credit facility. These actions are part of BMS's ongoing capital management strategy, occurring in the context of a proposed acquisition of Celgene Corporation.
Key Financial Metrics and Debt Structure
The filing focuses on liquidity and debt refinancing rather than operational performance metrics such as revenue or profit, which are not reported in this document.
- 364-Day Revolving Credit Facility: Replaces the existing facility maturing March 28, 2019. New maturity date is January 24, 2020. Interest margins range from 0.0% (base rate) to 0.625% - 1.0% (Eurodollar rate) based on credit ratings.
- Three-Year Revolving Credit Facility: New agreement maturing January 25, 2022. Interest margins range from 0.0% - 0.125% (base rate) to 0.75% - 1.125% (Eurodollar rate) based on credit ratings.
- Termination of Prior Facility: The previous 364-day facility was terminated on January 25, 2019. It remained undrawn at the time of termination, and no early termination penalties were incurred.
- Covenants: Both new agreements contain customary negative covenants (e.g., limitations on liens, mergers, and asset sales) and affirmative covenants (e.g., maintaining a long-term debt rating). Neither agreement includes financial covenants.
Material Changes Versus Prior Period
The primary material change is the refinancing of short-term liquidity. BMS replaced its existing 364-day revolving credit facility with a new 364-day facility and simultaneously established a new three-year revolving credit facility. The existing facility was terminated without penalty as it was undrawn. The new agreements extend the maturity profile of BMS's revolving credit capacity and adjust interest rate margins based on current credit ratings.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing references the proposed transaction with Celgene Corporation. Management expects to file a joint proxy statement/prospectus regarding this acquisition. Forward-looking statements in the filing address anticipated benefits, synergies, and the impact on the combined company's capital structure and leverage ratios.
Risks and Contingencies: The filing includes extensive cautionary statements regarding forward-looking information. Key risks include:
- Failure to satisfy conditions for the Celgene acquisition or delays in regulatory approvals.
- Inability to achieve projected synergies or successfully integrate Celgene's business.
- Potential decline in credit ratings for the combined company.
- Disruption to business operations and diversion of management attention due to the transaction.
- General market risks, including interest rate fluctuations, currency exchange rates, and changes in healthcare regulations.
Important Facts for Investor Verification
- Verify the specific terms and full text of the 364-Day and Three-Year Revolving Credit Facility Agreements filed as Exhibits 10.1 and 10.2.
- Monitor the status of the proposed Celgene Corporation acquisition, including the filing of the joint proxy statement/prospectus.
- Track BMS's credit ratings, as interest margins on the new facilities are directly tied to the company's non-credit enhanced senior unsecured long-term debt ratings.
- Review subsequent filings for updates on the integration of Celgene and the combined company's leverage ratio and debt repayment plans.